Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
BACKGROUND
In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype.


METHODS
The clinical, pathological and biological features of claudin-low tumors were compared to the other tumor subtypes using an updated human tumor database and multiple independent data sets. These main features of claudin-low tumors were also evaluated in a panel of breast cancer cell lines and genetically engineered mouse models.


RESULTS
Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features. Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation. They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors. Interestingly, we show that a group of highly utilized breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype. Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell.


CONCLUSIONS
These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines.
Prat
Aleix
A
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA.
Parker
Joel S
JS
Karginova
Olga
O
Fan
Cheng
C
Livasy
Chad
C
Herschkowitz
Jason I
JI
He
Xiaping
X
Perou
Charles M
CM
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D057167:Claudins / Q000378:metabolism*; D058750:Epithelial-Mesenchymal Transition; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D006801:Humans; D051379:Mice; D014411:Neoplastic Stem Cells / Q000378:metabolism; D010641:Phenotype; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D014408:Biomarkers, Tumor; D057167:Claudins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D066246:ErbB Receptors
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
10749912
N Engl J Med. 2006 Aug 10;355(6):560-9
16899776
Nature. 2009 Sep 24;461(7263):495-500
19741607
Breast Cancer Res. 2004;6(3):R149-56
15084238
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
12629218
Cancer Cell. 2007 Mar;11(3):259-73
17349583
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5
19666588
J Clin Oncol. 2009 Mar 10;27(8):1160-7
19204204
BMC Genomics. 2007 Jul 31;8:258
17663798
Cancer Res. 2006 Jan 1;66(1):41-5
16397213
Oncogene. 2007 Mar 29;26(14):2126-32
17016441
Lab Invest. 2008 Jun;88(6):591-601
18414401
BMC Genomics. 2006 Apr 27;7:96
16643655
Breast Cancer Res Treat. 2010 Aug;123(1):97-108
19911270
Cell. 2008 May 16;133(4):704-15
18485877
Nat Genet. 2000 Mar;24(3):227-35
10700174
Cell. 2009 Aug 21;138(4):645-659
19682730
Cancer Res. 2008 Feb 15;68(4):989-97
18281472
J Natl Cancer Inst. 2008 May 7;100(9):672-9
18445819
Nature. 2002 Jan 31;415(6871):530-6
11823860
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
17438091
Clin Cancer Res. 2010 Feb 1;16(3):876-87
20103682
Nature. 2000 Aug 17;406(6797):747-52
10963602
Nat Med. 1997 Jul;3(7):730-7
9212098
Cell Stem Cell. 2008 Jul 3;3(1):109-18
18593563
J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45
9701363
Genome Biol. 2003;4(5):P3
12734009
PLoS Biol. 2005 Jun;3(6):e187
15869330
Nat Med. 2009 Aug;15(8):907-13
19648928
Cell Stem Cell. 2007 Nov;1(5):555-67
18371393
Nat Med. 2009 Aug;15(8):842-4
19661985
Cancer Res. 2009 Feb 15;69(4):1302-13
19190339
BMC Genomics. 2006 May 16;7:115
16704732
PLoS One. 2008 Aug 06;3(8):e2888
18682804
J Natl Cancer Inst. 1977 Jun;58(6):1795-806
864756
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5
18230721
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Cancer Res. 2009 May 15;69(10):4116-24
19435916
Breast Cancer Res. 2008;10(2):R25
18366788
Nat Genet. 2008 May;40(5):499-507
18443585
Differentiation. 1998 Aug;63(4):201-13
9745711
Cancer Cell. 2006 Dec;10(6):515-27
17157791
Cancer Res. 2004 Jun 15;64(12):4218-26
15205334
In Vitro. 1974 Jan-Feb;9(4):239-45
4471183
Cancer Res. 2004 May 15;64(10):3479-85
15150101
N Engl J Med. 2002 Dec 19;347(25):1999-2009
12490681
Breast Cancer Res. 2008;10(5):R75
18782450
Nat Rev Cancer. 2009 Apr;9(4):265-73
19262571
J Clin Oncol. 2006 Sep 10;24(26):4236-44
16896004
J Pathol. 2008 Oct;216(2):141-50
18720457
Genes Dev. 2003 May 15;17(10):1253-70
12756227
Genome Biol. 2007;8(5):R76
17493263
JAMA. 2006 Jun 7;295(21):2492-502
16757721